Sastasundar Ventures Limited — Investor Meet, 16-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

SASTASUNDAR VENTURES LIMITED (soon to be Health X Platform Ltd) reported Q3 FY26 revenue of Rs. 341 Cr, up 22% YoY, with gross margin improving to 7.6%. EBITDA losses narrowed to negative Rs. 14 Cr, and EBIT turned positive at Rs. 1 Cr. For 9-month FY26, revenue was Rs. 928 Cr, and PAT reached positive Rs. 11 Cr.

Management highlighted sustained traction in B2B (Retailer Shakti) and B2C (SastaSundar) segments. Retailer Shakti aims for EBITDA break-even by Q4 FY26, while SastaSundar B2C targets contribution margin positive by FY27, with 100% growth next year. The company launched "JITO," a generic-generic brand expected to achieve 30% gross margins. Strategic focus remains on AI-enabled platforms, category/geographic expansion, and capital-efficient growth, exemplified by investing only Rs. 83 Cr in IPR business. Future plans include demerging the NBFC business.